[2-methyl-1-(4-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid methyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: [2-methyl-1-(4-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid methyl ester
• 英文别名: [2-methyl-1-(4-nitro-benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid methyl ester；methyl 2-[2-methyl-1-[(4-nitrophenyl)methyl]pyrrolo[2,3-b]pyridin-3-yl]acetate
• 化学式: C₁₈H₁₇N₃O₄
• 分子量: 339.351
• InChiKey: ZXXDIFINBGIJPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [2-methyl-1-(4-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid methyl ester 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 4.0h， 以95%的产率得到[2-methyl-1-(4-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid
  参考文献：
  名称：

  Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases

  摘要：

  Optimization of a 7-azaindole-3-acetic acid CRTh2 receptor antagonist chemotype derived from high throughput screening furnished a highly selective compound NVP-QAV680 with low nM functional potency for inhibition of CRTh2 driven human eosinophil and Th2 lymphocyte activation in vitro. The molecule exhibited good oral bioavailability in the rat, combined with efficacy in rodent CRTh2-dependent mechanistic and allergic disease models and was suitable for clinical development. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.025
• 作为产物：
  描述：

  对硝基溴化苄 在 2-叔丁基亚氨基-2-二乙基氨基-1,3-二甲基全氢-1,3,2-二氮杂磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.03h， 生成 [2-methyl-1-(4-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid methyl ester
  参考文献：
  名称：

  WO2007/68418

  摘要：

  公开号：

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2005123731A2

  公开（公告）日：2005-12-29

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明提供了公式（I）的化合物，以自由形式或盐形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如规范中所述，以及制备它们的过程，和它们作为药物的用途。
• Pyrrolopyridine Derivatives And Their Use As Crth2 Antagonists
  申请人：Bala Kamlesh Jagdis

  公开号：US20080114022A1

  公开（公告）日：2008-05-15

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明提供了公式（I）的化合物，以自由或盐形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如规范中所述，制备它们的过程以及它们作为药物的用途。
• Organic Compounds
  申请人：Sandham David Andrew

  公开号：US20080312230A1

  公开（公告）日：2008-12-18

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R 1 , R 2 R 3 R 4 , R 5 , R 6 , Q, X, m, n, and p are as described in the specification, on process for preparing them, and their use in the manufacture of a medicament for the treatment of neuropathic pain.

  根据本发明，提供了具有式（I）的化合物，以自由或盐形式存在，其中R1，R2R3R4，R5，R6，Q，X，m，n和p如规范中所述，以及制备它们的过程，并将它们用于制造用于治疗神经病性疼痛的药物。
• Organic compounds
  申请人：Bala Kamlesh Jagdis

  公开号：US20100210610A1

  公开（公告）日：2010-08-19

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明提供了式（I）的化合物，以自由形式或盐形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如说明书中所述，以及制备它们的过程和它们作为药物的用途。
• Pyrrolopyridine derivatives and their use as CRTH2 antagonists
  申请人：Bala Kamlesh Jagdis

  公开号：US08455645B2

  公开（公告）日：2013-06-04

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明，提供了式（I）的化合物，以自由或盐的形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如规范中所述，制备它们的过程以及它们作为药物的用途。